Pharming Leniolisib Launch Will Require Identifying Patients With Ultra Rare APDS
The company sees leniolisib as a way to expand its US and global commercial footprint before bringing in additional rare disease assets.
The company sees leniolisib as a way to expand its US and global commercial footprint before bringing in additional rare disease assets.